Prometheus Biosciences, Inc.

SSc-ILD Market Projected to Reach $750 Million by 2034 as Novel Therapies Enter Pipeline

a month ago

• The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market was valued at approximately $750 million in 2022 and is expected to grow significantly through 2034, driven by increasing disease prevalence and emerging therapies. • aTyr Pharma continues enrollment in its Phase 2 EFZO-CONNECT study evaluating efzofitimod for SSc-ILD, with participants receiving either 270mg, 450mg, or placebo administered intravenously over six monthly doses. • Several promising candidates in the pipeline, including PRA023, Belimumab, and Vixarelimab, are poised to reshape the treatment landscape for SSc-ILD, addressing significant unmet needs in this serious pulmonary complication.